Sign in
4

Changes in Ownership

SAB Biotherapeutics, Inc. Filed Acc 0000899243-22-011664

Options or other derivatives

  • Chief Business Officer acquired 23,453 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Finnegan Frederick Chief Business Officer 2022-03-16 Grant or award · Employee Stock Option (right to buy) +23,453 23,453 D
Loading xslF345X03/doc4.xml…